摘要
目的分析眼睑基底细胞癌(EBCC)患者术后复发风险的影响因素。方法收集66例EBCC患者的病历资料,免疫组化法检测跨膜蛋白16A(TMEM16A)、Ki-67和整合素连接激酶(ILK)表达情况。随访2年,记录EBCC患者的复发情况,其影响因素采用多元Logistic回归分析。结果随访2年,66例EBCC患者复发20例,未复发46例,复发率为30.30%(20/66)。复发与未复发EBCC患者年龄、吸烟史、饮酒史、家族史、白细胞介素-6(IL-6)水平、白细胞介素-1β(IL-1β)水平、转化生长因子-β1(TGF-β1)水平、TMEM16A表达情况、Ki-67表达情况、ILK表达情况比较,差异均有统计学意义(P﹤0.05)。多元Logistic回归分析结果显示,有吸烟史、有饮酒史、IL-6≥70 pg/ml、TMEM16A阳性表达、Ki-67阳性表达、ILK阳性表达均是EBCC患者复发的独立危险因素(P﹤0.05)。结论有吸烟史、有饮酒史、IL-6≥70 pg/ml、TMEM16A阳性表达、Ki-67阳性表达、ILK阳性表达均是EBCC患者复发的独立危险因素。
Objective To analyze the influencing factors for postoperative recurrence risk of basal cell carcinoma of eyelid(EBCC).Method A total of 66 patients with EBCC were collected,and the expression of transmembrane protein 16A(TMEM16A),Ki-67,integrin linked kinase(ILK)were detected by immunohistochemistry.Followed up for 2 years,the recurrence rate of EBCC patients were recorded,and the influencing factors of recurrence of EBCC patients were analyzed by multiple Logistic regression.Result After 2 years follow-up,among 66 patients of EBCC,20 patients were recurrenced,while 46 patients did not,the recurrence rate was 30.30%(20/66).The age,smoking history,alcohol consumption history,family history,interleukin-6(IL-6)levels,interleukin-1β(IL-1β)levels,transforming growth factor-1β(TGF-1β)levels,TMEM16A positive expression,Ki-67 positive expression,and ILK positive expression were different between recurrent and non-recurrent EBCC patients(P<0.05).Multiple Logistic regression analysis showed that smoking history,alcohol consumption history,IL-6≥70 pg/ml,TMEM16A positive expression,Ki-67 positive expression,and ILK positive expression were independent risk factors for recurrence in EBCC patients(P<0.05).Conclusion Smoking history,alcohol consumption history,IL-6≥70 pg/ml,TMEM16A positive expression,Ki-67 positive expression,and ILK positive expression are all independent risk factors for recurrence in EBCC patients.
作者
傅钢
唐东润
张玉梦
段海珍
FU Gang;TANG Dongrun;ZHANG Yumeng;DUAN Haizhen(Department of Ophthalmology,Shaanxi Second Provincial People’s Hospital,Xi’an 710005,Shaanxi,China;Department of Ophthalmology,Tianjin Medical University Eye Hospital,Tianjin 300392,China)
出处
《癌症进展》
2024年第4期375-379,共5页
Oncology Progress
基金
陕西省重点研发计划项目(S2021-ZDYF-0368)。